BCM
YMAB

Bayesian Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Bayesian Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,382
Closed -$63.7K – 915
2025
Q1 		$63.7K Buy
+14,382
New +$83.5K 0.01% 558

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Bayesian Capital Management's YMAB Position: Q2 2025 in Review

Bayesian Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 14,382 shares — an estimated $63.7K sold.

Bayesian Capital Management first reported a position in YMAB in Q1 2025 and held it in 1 quarter. The position peaked at $63.7K in Q1 2025. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

  • Bayesian Capital Management reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 14,382 Y-mAbs Therapeutics shares in Q2 2025, an estimated $63.7K.
  • Bayesian Capital Management first reported a position in Y-mAbs Therapeutics in Q1 2025 and held it in 1 quarter.
  • Bayesian Capital Management's Y-mAbs Therapeutics position peaked at $63.7K in Q1 2025.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.